2024-02-06 21:28:05 ET
Arrowhead Pharmaceuticals, Inc. (ARWR)
Q1 2024 Earnings Conference Call
February 6, 2024, 04:30 PM ET
Company Participants
Vince Anzalone - VP, IR
Chris Anzalone - President & CEO
Bruce Given - Chief Medical Scientist
James Hamilton - Chief Discovery & Translational Medicine
Ken Myszkowski - CFO
Conference Call Participants
Luca Issi - RBC Capital Markets
Edward Tenthoff - Piper Sandler
Mayank Mamtani - B. Riley Securities
Jason Gerberry - Bank of America Merrill Lynch
Patrick Trucchio - H.C. Wainwright & Company
Mani Foroohar - Leerink Partners
Mike Ulz - Morgan Stanley
Ellie Merle - UBS
Maury Raycroft - Jefferies
Prakhar Agrawal - Cantor Fitzgerald
William Pickering - Bernstein
Presentation
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone
Thank you, Annie. Good afternoon, everyone and thank you for joining us today to discuss Arrowhead's results for its fiscal 2024 first quarter ended December 31, 2023.
With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter. We also welcome back Dr. Bruce Given, who previously served as Arrowhead's Chief Operating Officer and Head of R&D, and who has rejoined the company n an interim basis as Chief Medical Scientist. Bruce will provide an update on our cardiometabolic pipeline. Dr. James Hamilton, our Chief of Discovery & Translational Medicine will provide an update on our earlier stage programs; and Ken Myszkowski, our Chief Financial Officer will give a review of the financials. In addition, Patrick O'Brien, our Chief Operating Officer and General Counsel will be available during the Q&A portion of the call.
Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.
I'd now like to turn the call over to Chris Anzalone, President and CEO of the company. Chris?
Chris Anzalone
Thanks, Vince. Good afternoon, everyone, and thank you for joining us today. Arrowhead has made a name for itself as a company capable of rapid innovation and development that is building a broad-based diverse business. This is exemplified by our '20 and '25 initiatives, where we expect to grow our pipeline of RNAi Therapeutics to at least 20 clinical stage or marketed products by the year 2025.
This commitment to creating a large number of new medicines as quickly as we can, speaks to our dual mandate; to maximize number of patients, we can help and to maximize our ability to create durable value for our shareholders. These mandates can be entirely aligned during early development. We decreased biology risk by focusing on well-validated targets, and our proven delivery platforms. At this stage, the cost of discovery and early development are relatively low, particularly when considering the potential value we can create with novel medicines. ...
Read the full article on Seeking Alpha
For further details see:
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript